GT201400166A - Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca - Google Patents
Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiacaInfo
- Publication number
- GT201400166A GT201400166A GT201400166A GT201400166A GT201400166A GT 201400166 A GT201400166 A GT 201400166A GT 201400166 A GT201400166 A GT 201400166A GT 201400166 A GT201400166 A GT 201400166A GT 201400166 A GT201400166 A GT 201400166A
- Authority
- GT
- Guatemala
- Prior art keywords
- apeline
- mimetics
- synthetic
- cardiac insufficiency
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES NOVEDOSAS QUE COMPRENDEN SECUENCIAS DE PÉPTIDOS Y POLIPÉPTIDOS MODIFICADAS DISEÑADAS PARA TRATAR ENFERMEDADES CARDIOVASCULARES EN LOS SUJETOS A QUIENES SE ADMINISTREN, Y LAS CUALES EXHIBEN UNA MAYOR RESISTENCIA A LA DEGRADACIÓN, Y UNA BIOACTIVIDAD EQUIVALENTE O MAYOR QUE SUS CONTRA-PARTES DE TIPO SILVESTRE. LA INVENCIÓN TAMBIÉN SE REFIERE A MÉTODS PARA LA ELABORACIÓN DE ESTAS COMPOSICIONES, Y AL USO DE ESTAS COMPOSICIONES COMO AGENTES FARMACÉUTICAMENTE ACTIVOS PARA TRATAR ENFERMEDADES CARDIOVASCULARES
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591557P | 2012-01-27 | 2012-01-27 | |
US201261717760P | 2012-10-24 | 2012-10-24 | |
US201261731697P | 2012-11-30 | 2012-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201400166A true GT201400166A (es) | 2015-10-15 |
Family
ID=47997598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201400166A GT201400166A (es) | 2012-01-27 | 2014-07-25 | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca |
Country Status (43)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
CN117045914A (zh) | 2011-07-13 | 2023-11-14 | 费雪派克医疗保健有限公司 | 加压气体源 |
US8921307B2 (en) * | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
BR112015011317A2 (pt) | 2012-11-30 | 2017-07-11 | Novartis Ag | métodos para preparar conjugados de proteínas contendo dissulfeto |
AU2013101734A4 (en) | 2012-12-18 | 2015-09-24 | Fisher & Paykel Healthcare Limited | Impeller and motor assembly |
WO2014099984A1 (en) * | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
AU2014236451B2 (en) | 2013-03-14 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
CN105612173A (zh) * | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的环状apelin衍生物 |
WO2015013169A2 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
MX2016001020A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca. |
JP6505692B2 (ja) * | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療のためのジスルフィド環状ポリペプチド |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
EP3071600B1 (en) | 2013-11-20 | 2020-06-17 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
ES2729643T3 (es) | 2013-11-26 | 2019-11-05 | Novartis Ag | Métodos para la conjugación de oxima con polipéptidos modificados con cetona |
WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
AU2015237357B2 (en) * | 2014-03-25 | 2019-04-18 | Lanthiopep B.V. | Cyclic apelin analogs |
GB201407532D0 (en) | 2014-04-29 | 2014-06-11 | Univ Ulster | Apelin analogues |
WO2015179734A1 (en) * | 2014-05-23 | 2015-11-26 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
EP3851445A1 (en) | 2014-06-23 | 2021-07-21 | Novartis AG | Site specific protein modifications |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
CR20170338A (es) * | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
USD790683S1 (en) * | 2015-03-11 | 2017-06-27 | Resmed Limited | Pressurized air delivery console |
ES2805743T3 (es) * | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
UA119932C2 (uk) | 2015-05-20 | 2019-08-27 | Емджен Інк. | Триазолові агоністи рецептора apj |
EP3416688B1 (en) | 2016-02-15 | 2022-08-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Apelin for use in the treatment of post-operative cognitive dysfunction |
US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
EP3528820B1 (en) | 2016-10-19 | 2023-10-04 | Avive, Inc. | Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases |
US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
US11400247B2 (en) | 2016-12-22 | 2022-08-02 | Fisher & Paykel Healthcare Limited | Breathing assistance apparatus |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
CN114288514A (zh) | 2017-04-23 | 2022-04-08 | 费雪派克医疗保健有限公司 | 呼吸辅助设备 |
EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
GB2610139B (en) | 2017-10-06 | 2023-06-07 | Fisher & Paykel Healthcare Ltd | Closed loop oxygen control |
WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
WO2020099929A1 (en) | 2018-11-14 | 2020-05-22 | Roivant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
EP3701992B1 (en) * | 2019-02-27 | 2023-07-05 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Gas delivery device with deformable bag and differential pressure sensors |
CN112007027B (zh) * | 2020-09-14 | 2022-07-15 | 长春金赛药业有限责任公司 | 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2128208C (en) | 1992-11-17 | 2004-01-06 | Ronald Godiska | Novel seven transmembrane receptors |
GB2281513B (en) * | 1993-08-31 | 1997-12-03 | Ulco Eng Pty Ltd | Ventilator disconnect alarm |
EP0645119A3 (en) * | 1993-09-27 | 1998-04-15 | Ohmeda Inc. | Disabling apnoea volume software |
US5598838A (en) * | 1995-04-07 | 1997-02-04 | Healthdyne Technologies, Inc. | Pressure support ventilatory assist system |
CA2222830C (en) * | 1996-12-02 | 2004-03-30 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
DE69838986T2 (de) | 1997-12-24 | 2009-01-08 | Takeda Pharmaceutical Co. Ltd. | Polypeptide, deren herstellung und verwendung |
AU5759399A (en) | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
KR20010080015A (ko) | 1998-10-05 | 2001-08-22 | 다케다 야쿠힌 고교 가부시키가이샤 | N-말단 메티오닌의 제거방법 |
US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
ATE326478T1 (de) | 2000-03-23 | 2006-06-15 | Takeda Chemical Industries Ltd | Peptidderivat |
WO2001090123A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the agtrl1 gene |
US6349724B1 (en) * | 2000-07-05 | 2002-02-26 | Compumedics Sleep Pty. Ltd. | Dual-pressure blower for positive air pressure device |
US7574368B2 (en) * | 2000-12-15 | 2009-08-11 | Ric Investments, Llc | System and method for upgrading a pressure generating system |
ES2320431T3 (es) | 2001-07-16 | 2009-05-22 | Caprotec Bioanalytics Gmbh | Compuestos de captura, colecciones de los mismos y metodos para analizar el proteoma y composiciones complejas. |
US7157035B2 (en) * | 2001-12-14 | 2007-01-02 | Fisher & Paykel Healthcare Limited | Method of forming a respiratory conduit |
TW545624U (en) * | 2002-01-18 | 2003-08-01 | Enermax Technology Corp | Computer environment temperature/rotation speed display and self-adjusted fan speed device |
WO2003063892A1 (fr) | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Utilisation d'apeline |
US7086399B2 (en) * | 2002-05-29 | 2006-08-08 | Fisher & Paykel Healthcare Limited | Apparatus for delivery of humidified gases therapy, associated methods and analysis tools |
JP2006523209A (ja) | 2003-03-12 | 2006-10-12 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | アペリン組成物によって血管新生を調節するための方法 |
US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
EP1656560A2 (en) | 2003-05-22 | 2006-05-17 | Agilent Technologies, Inc. | Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
EP1520861A1 (en) | 2003-09-11 | 2005-04-06 | Aventis Pharma Deutschland GmbH | Test system for the identification of APJ receptor ligands |
WO2005106493A1 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj) |
WO2006009902A2 (en) | 2004-06-17 | 2006-01-26 | Musc Foundation For Research Development | Non-natural amino acids |
WO2006023893A2 (en) | 2004-08-23 | 2006-03-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis and apoptosis with apelin compositions |
JP2008013436A (ja) | 2004-10-14 | 2008-01-24 | Kanazawa Univ | 血管形成促進剤 |
US20110097710A1 (en) | 2004-10-26 | 2011-04-28 | Macrae Calum A | Methods for detecting atrial fibrillation and related conditions |
US20060159676A1 (en) | 2005-01-14 | 2006-07-20 | Krieg Paul A | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
US20080031871A1 (en) | 2006-02-21 | 2008-02-07 | Allen Margaret L | Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene |
EP2017355A4 (en) | 2006-04-25 | 2010-01-06 | Univ Kyushu Nat Univ Corp | ASSOCIATED WITH ARTERIOSCLEROSIS DISEASE AND USE THEREOF |
WO2009033819A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
RU2010114036A (ru) | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | ПРИМЕНЕНИЕ ПЕПТИДА His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe ИНДИВИДУАЛЬНО ИЛИ В СОЧЕТАНИИ С ПЕПТИДОМ Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА |
US20110123534A1 (en) | 2007-12-12 | 2011-05-26 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
JP2012507523A (ja) | 2008-11-04 | 2012-03-29 | アンカー セラピューティクス,インコーポレイテッド | Apj受容体化合物 |
WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
JP2013509874A (ja) | 2009-11-04 | 2013-03-21 | エラスムス ユニバーシティ メディカル センター ロッテルダム | 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法 |
WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
RU2457216C1 (ru) | 2010-12-21 | 2012-07-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | Додекапептиды, обладающие кардиопротекторными свойствами |
EP2802596A1 (en) | 2012-01-09 | 2014-11-19 | Anchor Therapeutics, Inc. | Apj receptor compounds |
CN105612173A (zh) | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的环状apelin衍生物 |
WO2015013169A2 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
MX2016001020A (es) | 2013-07-25 | 2016-08-03 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca. |
JP6505692B2 (ja) | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療のためのジスルフィド環状ポリペプチド |
-
2013
- 2013-01-23 US US13/747,621 patent/US8673848B2/en active Active
- 2013-01-24 UY UY0001034593A patent/UY34593A/es not_active Application Discontinuation
- 2013-01-24 JO JOP/2013/0027A patent/JO3380B1/ar active
- 2013-01-25 CN CN201380016261.6A patent/CN104220452B/zh active Active
- 2013-01-25 KR KR1020197037887A patent/KR20200003229A/ko not_active Application Discontinuation
- 2013-01-25 CA CA2862240A patent/CA2862240A1/en active Pending
- 2013-01-25 NZ NZ627772A patent/NZ627772A/en not_active IP Right Cessation
- 2013-01-25 AP AP2014007846A patent/AP2014007846A0/xx unknown
- 2013-01-25 CU CUP2014000097A patent/CU24266B1/es unknown
- 2013-01-25 RS RS20180546A patent/RS57200B1/sr unknown
- 2013-01-25 DK DK13711953.3T patent/DK2807183T3/en active
- 2013-01-25 MY MYPI2014002154A patent/MY172268A/en unknown
- 2013-01-25 HU HUE13711953A patent/HUE039137T2/hu unknown
- 2013-01-25 UA UAA201408328A patent/UA116196C2/uk unknown
- 2013-01-25 LT LTEP13711953.3T patent/LT2807183T/lt unknown
- 2013-01-25 WO PCT/IB2013/050666 patent/WO2013111110A2/en active Application Filing
- 2013-01-25 EA EA201491433A patent/EA027853B1/ru not_active IP Right Cessation
- 2013-01-25 JP JP2014553847A patent/JP6313222B2/ja active Active
- 2013-01-25 TW TW102103025A patent/TWI576356B/zh not_active IP Right Cessation
- 2013-01-25 ES ES13711953.3T patent/ES2670832T3/es active Active
- 2013-01-25 SI SI201330999T patent/SI2807183T1/en unknown
- 2013-01-25 SG SG11201404369PA patent/SG11201404369PA/en unknown
- 2013-01-25 TR TR2018/07309T patent/TR201807309T4/tr unknown
- 2013-01-25 KR KR1020147023505A patent/KR102068370B1/ko active IP Right Grant
- 2013-01-25 PE PE2014001176A patent/PE20142194A1/es active IP Right Grant
- 2013-01-25 PL PL13711953T patent/PL2807183T3/pl unknown
- 2013-01-25 EP EP13711953.3A patent/EP2807183B1/en active Active
- 2013-01-25 AR ARP130100228A patent/AR089808A1/es unknown
- 2013-01-25 MX MX2014009085A patent/MX351569B/es active IP Right Grant
- 2013-01-25 BR BR112014018306A patent/BR112014018306A8/pt not_active Application Discontinuation
- 2013-01-25 AU AU2013213265A patent/AU2013213265C1/en not_active Ceased
- 2013-01-25 PT PT137119533T patent/PT2807183T/pt unknown
-
2014
- 2014-01-28 US US14/165,680 patent/US9067971B2/en active Active
- 2014-07-22 ZA ZA2014/05400A patent/ZA201405400B/en unknown
- 2014-07-23 TN TNP2014000318A patent/TN2014000318A1/fr unknown
- 2014-07-24 IL IL233792A patent/IL233792B/en active IP Right Grant
- 2014-07-25 GT GT201400166A patent/GT201400166A/es unknown
- 2014-07-25 CL CL2014001994A patent/CL2014001994A1/es unknown
- 2014-07-25 PH PH12014501701A patent/PH12014501701A1/en unknown
- 2014-07-28 CR CR20140364A patent/CR20140364A/es unknown
- 2014-07-31 CO CO14167109A patent/CO7020879A2/es unknown
- 2014-08-27 EC ECIEPI201416014A patent/ECSP14016014A/es unknown
-
2015
- 2015-01-28 HK HK15100964.5A patent/HK1200470A1/xx not_active IP Right Cessation
- 2015-05-18 US US14/714,914 patent/US9982017B2/en active Active
-
2017
- 2017-05-01 US US15/583,408 patent/US20170232221A1/en not_active Abandoned
- 2017-10-06 JP JP2017195815A patent/JP6595553B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-22 HR HRP20180806TT patent/HRP20180806T1/hr unknown
- 2018-05-24 CY CY20181100556T patent/CY1120239T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2012002037A1 (es) | Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
CR20150386A (es) | Composiciones de nanoparticulas de albumina y paclitaxel | |
CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
ECSP14000357A (es) | Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
PE20151023A1 (es) | Triazolopirazinas | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
CL2014000432A1 (es) | Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. | |
EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
CL2013000881A1 (es) | Combinaciones farmacéuticas que comprenden un componente (a) que corresponden a compuestos derivados de difenilurea omega-carboxiaril-sustituidos, (b) compuestos derivados de n-(2-arilamino)arilsulfonamida y (c) que son uno o más agentes farmaceuticos adicionales; y su uso en el tratamiento del cancer | |
DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. |